Population Diversity and Pharmacogenomics in Africa

Handbook of Pharmacogenomics and Stratified Medicine

Volumn , Issue , 2014, Pages 971-998

  Masimirembwa, Collen ^a   Dandara, Collet ^b   Hasler, Julia ^a  

^a African Institute of Biomedical Science and Technology ^*  (Zimbabwe)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

African populations; Drug metabolism; Drug safety; Epigenetics; Genetic diversity; Nongenetic diversity; Pharmacogenetics; Pharmacogenomics; Stratified medicine

Indexed keywords

EID: 84919380415     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386882-4.00043-8     Document Type: Chapter

References (101)

1. Cavalli-Sforza LL, Piazza A, Menozzi P History and geography of human genes 1994, Princeton University Press.
2. Campbell MC, Tishkoff SA The evolution of human genetic and phenotypic variation in Africa. Curr Biol 2010, 2010(20):R166-R173.
3. Prugnolle F, Manica A, Balloux F Geography predicts neutral genetic diversity of human populations. Curr Biol 2005, 15(5):R159-R160.
4. Betti L, Balloux F, Amos W, Hanihara T, Manica A Distance from Africa, not climate, explains within-population phenotypic diversity in humans. Proc Biol Sci 2009, 276(1658):809-814.
5. Tishkof SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, et al. The genetic structure and history of Africans and African Americans. Science 2009, 324(5930):1035-1044.
6. Lock M The art of medicine-the lure of the epigenome. Lancet 2013, 381:1896-1897.
7. Labonté B, Suderman M, Maussion G, Navaro L, Yerko V, Mahar I, et al. Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry 2012, 69:722-731.
8. Meaney MJ Epigenetics and the biological definition of gene x environment interactions. Child Dev 2010, 81:41-79.
9. Moshe S The early life social environment and DNA methylation. Epigenetics 2011, 6:1-8.
10. Nieminen TT, Shoman S, Eissa S, Peltomäki P, Abdel-Rahman WM Distinct genetic and epigenetic signatures of colorectal cancers according to ethnic origen. Cancer Epidemiol Biomarkers Prev 2012, 21(202-211):011.
11. Mobio TA, Anane R, Baudrimont I, Carratú MR, Shier TW, Dano SD, et al. Epigenetic properties of fumonisin B(1): cell cycle arrest and DNA base modification in C6 glioma cells. Toxicol Appl Pharmacol 2000, 164(1):91-96.
12. Webb JLA Historical epidemiology and infectious disease processes in Africa. J Afr Hist 2013, 54:3-10.
13. African world heritage-a remarkable diversity, UNESCO Publishing; 2013. http://publishing.unesco.org/details.aspx?&Code_Livre=4959&change=E.
14. Cashdan E Ethnic diversity and its environmental determinants: effects of climate change, pathogens, and habitat diversity. Am Anthropol 2001, 103:968-991.
15. African languages: an introduction 2000, Cambridge University Press. B. Heine, D. Nurse (Eds.).
16. Fearon JD Ethnic and cultural diversity by country. J Econ Growth 2003, 8:195-222.
17. Posner D Measuring ethnic fractionalization in Africa. Am J Polit Sci 2004, 48(4):849-863.
18. Roeder PG. Ethnolinguistic fractionalization (ELF) indices, 1961 and 1985. 2001 [24.04.2003]. http://weber.ucsd.edu/~proeder/elf.htm.
19. Alesina A, Devleeschauwer A, Easterly W, Kurlat S, Wacziarg R Fractionalization. J Econ Growth 2003, 8:155-194.
20. Campbell MC, Tishkoff SA African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008, 9:403-433.
21. Rosa A, Brehm A African human mtDNA phylogeography at-a-glance. J Anthropol Sci 2011, 89:25-58.
22. UN Department of Economic and Social Affairs, Population Division. See and. http://esa.un.org/wup2009/unup/index.asp?panel=1.
23. WHO Health Data and Statistics,. http://www.who.int/healthinfo/statistics/en/.
24. UN Department of Economic and Social Affairs, Population Division. Population aging and development 2012, Wall chart. http://www.un.org/en/development/desa/population/publications/pdf/ageing/2012PopAgeingandDev_WallChart.pdf.
25. WHO Global burden of disease,. http://www.who.int/topics/global_burden_of_disease/en/.
26. WHO World Health Statistics. Global health indicators part III, WHO report, 2013. http://www.who.int/gho.
27. WHO Cause-specific mortality and morbidity: HIV/AIDS, malaria and TB. http://apps.who.int/gho/data/node.main.27?lang=en.
28. Taylor AL, Ziesche S, Yancy C, Carson P, D'agostino R, Ferdinand K, et al. African-American heart failure trial investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
29. Exner DV, Dries DL, Domanski MJ, Cohn JN Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344:1351-1357.
30. Zoratti R A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin?. Eur J Epidemiol 1998, 14(1):9-21.
31. Gaines K, Burke G Ethnic differences in stroke: black-white differences in the United States population. SECORDS investigators. Southeastern consortium on racial differences in stroke. Neuroepidemiology 1995, 14(5):209-239.
32. Scheinfeldt LB, Soi S, Tishkoff SA Working towards a synthesis of archeological, linguistic, and genetic data for inferring African population history. PNAS 2010, 107:8931-8938.
33. Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN, et al. Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 2008, 16:780-783.
34. Maimbo M, Mushiroda T, Takahashi A, Kubo M, Sayi J, Bolaji OO, et al. A comprehensive genome-wide study of the genetic structure of individuals from 10 African ethnic groups, manuscript in preparation.
35. Bryc K, Auton A, Nelson MR, Oksenberg JR, Hauser SL, Williams S, et al. Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci USA 2010, 12:786-791.
36. Fage JD A history of Africa. West Africa during the slave trade era 1990, 266. Unwin Hyman, [Chapter 11].
37. Tishkoff SA, Gonder MK, Henn BM, Mortensen H, Knight A, Gignoux C, et al. History of click-speaking populations of Africa inferred from mtDNA and Y chromosome genetic variation. Mol Biol Evol 2007, 24:2180-2195.
38. Ambrose S Chronology of the Later Stone Age and food production in East Africa. J Arch Sci 1998, 25:377-391.
39. Gifford-Gonzalez D African archeology. Blackwell 2005, 187-224.
40. Hansen NT, Brunak S, Altman RB Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 2009, 86(2):183-189.
41. Kitzmiller JP, Groen DK, Phelps MA, Sadee W Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 2011, 78(4):243-257.
42. Hernandez-Boussard T, Woon M, Klein TE, Altman RB Integrating large-scale genotype and phenotype data. OMICS 2006, 10(4):545-554.
43. Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 2007, 60(3):599-604.
44. Kudzi W, Dodoo AN, Mills JJ Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009, 10:124.
45. Kudzi W, Dodoo AN, Mills JJ Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?. BMC Med Genet 2010, 11:111.
46. Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N, et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011, 66(10):2350-2361.
47. Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa Populations. PLoS ONE 2013, 8(7).
48. Swart M, Ren Y, Smith P, Dandara C ABCB1 4036A>G and 1236C>T Polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients. Front Genet 2012, 3:236.
49. Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 2013, 23(8):415-427.
50. Swart M, Whitehorn H, Ren Y, Smith P, Ramesar RS, Dandara C PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 2012, 13:112.
51. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2012, 12(6):499-506.
52. Kampira E, Kumwenda J, van Oosterhout JJ, Dandara C Mitochondrial DNA subhaplo groups L0a2 and L2a modify susceptibility to peripheral neuropathy in Malawian adults on stavudine containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2013, 63:647-652.
53. Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J, et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis 2013, 13:261.
54. Rendic S, Guengerich FP Update information on drug metabolism systems-2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010, 11(1):4-84.
55. Lynch T, Price A The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007, 76(3):391-396.
56. Bains RK, Kovacevic M, Plaster CA, Tarekegn A, Bekele E, Bradman NN, et al. Molecular diversity and population structure at the cytochrome P450 3A5 gene in Africa. BMC Genet 2013, 14:34.
57. Swen JJ, Nijenhuis M, DeBoer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011, 89(5):662-673.
58. Alessandrini M, Asfaha S, Dodgen TM, Warnich L, Pepper MS Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 2013, 45(2):253-275.
59. Masimirembwa CM, Hasler JA Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997, 44(5):561-571.
60. Aklillu E, Dandara C, Bertilsson L, Masimirembwa C Pharmacogenetics of cytochrome P450s in African populations: clinical and molecular evolutionary implications. Chapter category: pharmacogenomics. Pharmacogenomics in admixed populations 1990, 99. Landes Bioscience, [Chapter 7]. G. Suarez-Kurtz (Ed.).
61. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993, 3(6):275-280.
62. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995, 57(6):656-661.
63. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996, 42(6):713-719.
64. Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996, 51(2):117-122.
65. Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001, 57(1):11-17.
66. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 1999, 9(6):715-723.
67. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 1999, 48(3):395-401.
68. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 1998, 64(4):391-401.
69. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 2002, 12(5):375-383.
70. Simooya OO, Njunju E, Hodjegan AR, Lennard MS, Tucker GT Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993, 3(4):205-208.
71. Simooya OO, Sijumbil G, Lennard MS, Tucker GT Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol 1998, 45(3):315-317.
72. Gaedigk A, Coetsee C The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 2008, 64(5):465-475.
73. Wright GE, Niehaus DJ, Drögemöller BI, Koen L, Gaedigk A, Warnich L Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010, 74(4):340-350.
74. Dodgen TM, Hochfeld WE, Fickl H, Asfaha SM, Durandt C, Rheeder P, et al. Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet 2013, 14:20.
75. Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, et al. The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002, 71(1):77-88.
76. Bapiro TE, Hasler JA, Ridderström M, Masimirembwa CM The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol 2002, 64:1387-1398.
77. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004, 75(6):1059-1069.
78. Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012, 67(9):2213-2221.
79. Nemaura T, Nhachi C, Masimirembwa C Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: implications for individualising therapy. Afr J Pharm Pharmacol 2012, 6(29):2188-2193.
80. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, et al. Swiss HIV cohort study. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009, 19(4):300-309.
81. Gounden V, van Niekerk C, Snyman T, George JA Presence of the CYP2B6 516G> T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010, 7:32.
82. Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008, 64(4):357-365.
83. Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C Y N: CYP2B6 genotype is a strong predictor of systemic exposure 5 to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 2012, 68:267-271.
84. Stingl JC, Brockmöller J, Viviani R Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 2013, 18(3):273-287.
85. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical pharmacogenetics implementation consortium. Clin Pharmacol Ther 2013, 93(5):402-408.
86. Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 2001, 11(5):417-427.
87. Kirchheiner J, Brockmöller J Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005, 77(1):1-16.
88. Yin T, Miyata T Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 2007, 120(1):1-10.
89. Speed WC, Kang SP, Tuck DP, Harris LN, Kidd KK Global variation in CYP2C8-CYP2C9 functional haplotypes. Pharmacogenomics J 2009, 9(4):283-290.
90. Aithal GP, Day CP, Kesteven PJ, Daly AK Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353(9154):717-719.
91. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009, 10(2):261-266.
92. Dang MT, Hambleton J, Kayser SR The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005, 39:1008-1012.
93. Absher RK, Moore ME, Parker MH Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002, 36:1512-1517.
94. Dandara C, Masimirembwa CM, Magimba A, Kaaya S, Sayi J, Sommers DK, et al. Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A. Pharmacogenetics 2003, 13(1):55-58.
95. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?. Antimicrob Agents Chemother 2005, 49(5):1733-1738.
96. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. Pharmacogenetics-based tuberculosis therapy research group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013, 69(5):1091-1101.
97. Gomez A, Ingelman-Sundberg M Pharmacoepigenetics: its role in interindividual differences in drug response. Clin pharmacol Therapeut 2009, 85(4):426-430.
98. Baer-Dubowska W, Majchrzak-Celińska A, Cichocki M Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep 2011, 63(2):293-304.
99. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 2012, 22(3):198-205.
100. Wang L, McLeod HL, Weinshilboum RM Genomic medicine: genomics and drug response. N Engl J Med 2011, 364:1144-1153.
101. Huang RS, Dolan ME Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics 2010, 11(4):471-474.